Methods of treating hypertriglyceridemia

Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

1 .- 10 . (canceled) 
     
     
         11 . A method of reducing LDL-P in a subject in need thereof, comprising:
 determining a baseline LDL-P level associated with the subject; and   administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.   
     
     
         12 . The method of  claim 11 , further comprising, measuring a baseline lipid profile in the subject prior to administering the pharmaceutical composition to the subject. 
     
     
         13 . The method of  claim 11 , wherein after administration of the pharmaceutical composition, the subject experiences a reduction in LDL-P of at least about 5% compared to baseline. 
     
     
         14 . The method of  claim 13 , wherein the reduction in LDL-P of at least about  5 % compared to baseline is actual % change or median % change. 
     
     
         15 . The method of  claim 11 , wherein the subject is administered 2 g to about 4 g of ethyl eicosapentaenoate per day. 
     
     
         16 . The method of  claim 11 , wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day. 
     
     
         17 . The method of  claim 11 , wherein the ethyl eicosapentaenoate comprises at least about 90%, by weight, of all fatty acids in the pharmaceutical composition. 
     
     
         18 . The method of  claim 17 , wherein docosahexaenoic acid and its derivatives comprise no more than about 10%, by weight, of all fatty acids in the pharmaceutical composition. 
     
     
         19 . The method of  claim 18 , wherein the pharmaceutical composition is present in a capsule. 
     
     
         20 . The method of  claim 16 , wherein the subject is not on concomitant lipid-altering therapy. 
     
     
         21 . The method of  claim 20 , wherein the subject is diabetic. 
     
     
         22 . The method of  claim 19 , wherein the pharmaceutical composition is packaged in blister packages of about 1 to less than about 20 capsules per sheet.